Edition:
United Kingdom

People: Chimerix Inc (CMRX.OQ)

CMRX.OQ on NASDAQ Stock Exchange Global Market

2.20USD
23 Aug 2019
Change (% chg)

$-0.15 (-6.38%)
Prev Close
$2.35
Open
$2.35
Day's High
$2.47
Day's Low
$2.18
Volume
127,992
Avg. Vol
106,303
52-wk High
$4.39
52-wk Low
$1.75

Ware, Roy 

Dr. Roy W. Ware, Ph.D., MBA, serves as Chief Manufacturing and Technology Officer of the Company. Dr. Ware will oversee manufacturing, clinical trial material sourcing, medicinal and process chemistry, and analytical and pharmaceutical development. Together they will lead the Chimerix Discovery effort. In his previous position as Vice President, Chemistry at Chimerix, Dr. Ware led the chemistry effort for discovery and development programs, including structure/activity evaluation, chemical process development, and manufacturing of CMX521. He also contributed to the patent programs for brincidofovir, securing a patent extension to 2034, and CMX157 (licensed to ContraVir), securing a patent extension to 2033. Prior to joining Chimerix, Dr. Ware held multiple positions in research including as a research scientist at PharmaCore, Inc.; as a consultant to Scynexis, Inc. working in chemical process development and cGMP synthesis; and leading a team of medicinal chemists working on preclinical oncology and malaria programs, as well as contributing to the expansion of patent coverage for the proteome mining technology at Serenex, Inc. Dr. Ware also worked in the area of drug addiction therapy as a postdoctoral researcher at the Research Triangle Institute. Dr. Ware received his B.A. in Chemistry from the University of North Carolina at Greensboro, his PhD in Chemistry from Wake Forest University, and his M.B.A. from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --